KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Net Cash Flow (2016 - 2026)

Gsk has reported Net Cash Flow over the past 18 years, most recently at $210.3 million for Q1 2026.

  • For Q1 2026, Net Cash Flow fell 83.55% year-over-year to $210.3 million; the TTM value through Mar 2026 reached $6.7 billion, up 13.29%, while the annual FY2025 figure was -$235.4 million, 130.62% down from the prior year.
  • Net Cash Flow for Q1 2026 was $210.3 million at Gsk, down from $650.5 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $9.6 billion in Q1 2022 and troughed at -$533.6 million in Q1 2023.
  • A 5-year average of $2.0 billion and a median of $1.6 billion in 2023 define the central range for Net Cash Flow.
  • Biggest five-year swings in Net Cash Flow: tumbled 105.57% in 2023 and later skyrocketed 1314.2% in 2025.
  • Year by year, Net Cash Flow stood at $2.1 billion in 2022, then dropped by 9.39% to $1.9 billion in 2023, then tumbled by 79.41% to $392.8 million in 2024, then skyrocketed by 65.61% to $650.5 million in 2025, then tumbled by 67.67% to $210.3 million in 2026.
  • Business Quant data shows Net Cash Flow for GSK at $210.3 million in Q1 2026, $650.5 million in Q4 2025, and $3.0 billion in Q3 2025.